IPC Councilors play an essential role in the work of IPC. IPC Councilors serve in an advisory capacity and lend their global expertise on psoriasis research, treatment, and education to support all IPC programs, events, and initiatives. They provide expert opinions on current psoriasis therapeutic and research-related issues, participate in round-table conferences, contribute to manuscripts submitted to top-tier journals, and present at important congresses around the world. Learn more about our global volunteer network by searching the Meet the Experts directory.
The IPC Board seeks colleagues who hold a position in a professional specialty relevant to IPC’s mission. The individual either manages the care of people with psoriasis or psoriatic arthritis or performs research relevant to psoriasis and its multiple comorbidities.
Councilor selection is based on demonstrated expertise and leadership in the field of psoriasis or one of its comorbidities. To be considered, candidates must meet at least three of the following criteria:
These criteria reflect IPC’s commitment to recognizing well-established individuals who have contributed substantially to the psoriasis field through research, education, clinical practice, and professional leadership.
Please note: Because IPC conducts its activities in English—including meetings, publications, and collaborative work—proficiency in English is required for all Councilors. This ensures full participation and effective communication across IPC’s global network.
Councilors wishing to remain active must participate in one IPC activity over two years.
Activities may include:
Candidates must:
The IPC Executive Team will screen each application and CV to confirm eligibility. If necessary, additional information will be requested to support your application. The IPC Membership Committee will review eligible applications and make recommendations to the IPC Board of Directors on a quarterly basis.
Final approval of candidacy for all IPC Councilors is at the discretion of the IPC Board of Directors.
A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.
In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.
Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.
IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.
In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.
